Clinical Trial Update: GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on GX-I7 in combination with bevacizumab for recurrent glioblastoma is reported as ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• GX-I7

Snippet

Sponsor: Genexine, Inc. | Conditions: Recurrent Glioblastoma | Phase 2 | Status: UNKNOWN